MediWound Company Profile (NASDAQ:MDWD)

About MediWound (NASDAQ:MDWD)

MediWound logoMediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MDWD
  • CUSIP: N/A
  • Web:
  • Market Cap: $109.77 million
  • Outstanding Shares: 21,954,000
Average Prices:
  • 50 Day Moving Avg: $6.30
  • 200 Day Moving Avg: $6.53
  • 52 Week Range: $4.25 - $8.58
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.94
  • P/E Growth: -0.07
Sales & Book Value:
  • Annual Revenue: $2.17 million
  • Price / Sales: 50.59
  • Book Value: ($0.02) per share
  • Price / Book: -250.00
  • EBIDTA: ($16,180,000.00)
  • Net Margins: -752.78%
  • Return on Equity: -326.32%
  • Return on Assets: -48.65%
  • Current Ratio: 5.94%
  • Quick Ratio: 5.68%
  • Average Volume: 48,506 shs.
  • Beta: 0.11
  • Short Ratio: 2.97

Frequently Asked Questions for MediWound (NASDAQ:MDWD)

What is MediWound's stock symbol?

MediWound trades on the NASDAQ under the ticker symbol "MDWD."

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) posted its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.01. The firm had revenue of $0.69 million for the quarter, compared to the consensus estimate of $0.69 million. MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. The business's revenue was up 93.8% compared to the same quarter last year. During the same period last year, the company posted ($0.34) earnings per share. View MediWound's Earnings History.

When will MediWound make its next earnings announcement?

MediWound is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for MediWound.

Where is MediWound's stock going? Where will MediWound's stock price be in 2017?

4 brokers have issued 12-month target prices for MediWound's shares. Their predictions range from $10.00 to $11.00. On average, they anticipate MediWound's share price to reach $10.33 in the next twelve months. View Analyst Ratings for MediWound.

Who are some of MediWound's key competitors?

Who are MediWound's key executives?

MediWound's management team includes the folowing people:

  • Aharon Yaari, Chairman of the Board
  • Cal Cohen, Chief Executive Officer
  • Sharon Malka, Chief Financial Officer
  • Eilon Asculai, Vice President, Research & Development
  • Lior Rosenberg, Chief Medical Officer
  • Vickie R. Driver, Director
  • Stephen T. Wills CPA, Director

Who owns MediWound stock?

MediWound's stock is owned by many different of retail and institutional investors. Top institutional investors include Migdal Insurance & Financial Holdings Ltd. (9.24%), YELIN LAPIDOT HOLDINGS MANAGEMENT LTD. (5.70%), California Public Employees Retirement System (0.91%), Broadfin Capital LLC (0.80%), Wells Fargo & Company MN (0.30%) and Oppenheimer & Co. Inc. (0.11%). View Institutional Ownership Trends for MediWound.

Who sold MediWound stock? Who is selling MediWound stock?

MediWound's stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC and Oppenheimer & Co. Inc.. View Insider Buying and Selling for MediWound.

Who bought MediWound stock? Who is buying MediWound stock?

MediWound's stock was bought by a variety of institutional investors in the last quarter, including Migdal Insurance & Financial Holdings Ltd. and Wells Fargo & Company MN. View Insider Buying and Selling for MediWound.

How do I buy MediWound stock?

Shares of MediWound can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MediWound's stock price today?

One share of MediWound stock can currently be purchased for approximately $5.00.

MarketBeat Community Rating for MediWound (NASDAQ MDWD)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  202
MarketBeat's community ratings are surveys of what our community members think about MediWound and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for MediWound (NASDAQ:MDWD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.33 (106.67% upside)

Analysts' Ratings History for MediWound (NASDAQ:MDWD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/18/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$10.00LowView Rating Details
8/25/2017Jefferies Group LLCSet Price TargetBuy$10.00HighView Rating Details
6/26/2017SunTrust Banks, Inc.Reiterated RatingBuyLowView Rating Details
5/25/2017AegisReiterated RatingBuy$11.00LowView Rating Details
8/17/2016Wells Fargo & CompanyInitiated CoverageOutperform$14.00N/AView Rating Details
4/23/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 9/22/2015 forward)


Earnings History for MediWound (NASDAQ:MDWD)
Earnings by Quarter for MediWound (NASDAQ:MDWD)
Earnings History by Quarter for MediWound (NASDAQ MDWD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/20176/30/2017($0.19)($0.20)$0.69 million$0.69 millionViewListenView Earnings Details
5/8/20173/31/2017($0.17)($0.20)$0.56 million$0.54 millionViewListenView Earnings Details
2/21/201712/31/2016($0.25)($0.09)$0.73 million$0.43 millionViewListenView Earnings Details
11/14/2016Q316($0.26)($0.26)$0.61 million$0.52 millionViewN/AView Earnings Details
7/28/2016Q216($0.23)($0.34)$0.45 million$3.36 millionViewListenView Earnings Details
4/21/2016Q116($0.24)($0.17)$0.28 million$0.25 millionViewListenView Earnings Details
1/25/2016Q415($0.23)($0.36)$0.40 million$0.27 millionViewListenView Earnings Details
10/27/2015Q315($0.31)($0.17)$0.47 million$334.00 millionViewListenView Earnings Details
8/3/2015Q215($0.26)($0.19)$0.22 million$0.17 millionViewListenView Earnings Details
5/4/2015Q1 2015($0.30)($0.28)$0.18 million$0.07 millionViewListenView Earnings Details
2/12/2015Q4($0.26)($0.33)$0.10 million$0.12 millionViewListenView Earnings Details
11/5/2014Q3($0.25)($0.24)$0.31 million$0.05 millionViewListenView Earnings Details
7/31/2014Q2($0.15)($0.28)$0.19 million$0.89 millionViewListenView Earnings Details
5/2/2014Q1 2014($0.11)($0.05)$0.05 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for MediWound (NASDAQ:MDWD)
2017 EPS Consensus Estimate: ($0.72)
2018 EPS Consensus Estimate: ($0.48)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.19)($0.10)($0.16)
Q2 20173($0.21)($0.13)($0.18)
Q3 20173($0.20)($0.19)($0.20)
Q4 20173($0.21)($0.17)($0.19)
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.15)($0.15)($0.15)
Q3 20181($0.12)($0.12)($0.12)
Q4 20181($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)


Dividend History for MediWound (NASDAQ:MDWD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for MediWound (NASDAQ:MDWD)
No insider trades for this company have been tracked by


Headline Trends for MediWound (NASDAQ:MDWD)
Latest Headlines for MediWound (NASDAQ:MDWD)
DateHeadline logoResearch Analysts Offer Predictions for MediWound Ltd.'s FY2017 Earnings (MDWD) - September 22 at 7:22 AM logoResearch Analysts Set Expectations for MediWound Ltd.'s Q1 2018 Earnings (MDWD) - September 20 at 8:58 AM logoMediWound Secondary Capitalizes on 2017 Success - September 20 at 6:13 AM logoMediWound (MDWD) Announces Common Share Offering - September 20 at 6:13 AM logoAll You Need To Know About MediWound Ltd’s (MDWD) Risks - September 20 at 6:13 AM logoMediWound Ltd. to Post Q3 2018 Earnings of ($0.12) Per Share, Oppenheimer Holdings Forecasts (MDWD) - September 19 at 10:12 AM logoMediWound Ltd. Announces Pricing of $22 Million Public Offering of Ordinary Shares - September 19 at 7:43 AM logoMediWound Ltd. :MDWD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 - September 18 at 9:14 PM logoMediWound Ltd. Announces Public Offering of Ordinary Shares - September 18 at 9:14 PM logoMediWound Ltd. (MDWD) Receives "Buy" Rating from Oppenheimer Holdings, Inc. - September 18 at 8:58 PM logoZacks: Brokerages Expect MediWound Ltd. (MDWD) Will Post Quarterly Sales of $740,000.00 - September 17 at 3:16 AM logoHead to Head Review: MediWound (MDWD) & Sonoma Pharmaceuticals (SNOA) - September 14 at 4:18 AM logoMediWound’s NexoBrid® Wins Best Poster Presentation Award at the 17th European Burns Association Congress - September 12 at 1:04 AM logoMediWound’s NexoBrid® Highlighted in 43 Presentations at the 17th European Burns Association Congress - September 7 at 1:39 AM logoContrasting MediWound (MDWD) and Tokai Pharmaceuticals (NVUS) - September 6 at 6:26 PM logoMediWound (MDWD) Completes Second Cohort of EscharEx Phase 2 Study - September 3 at 7:40 PM logoMediWound Successfully Completes Second Cohort of EscharEx® Phase 2 Study - September 2 at 6:11 AM logoMediWound Ltd. (MDWD) Expected to Announce Quarterly Sales of $740,000.00 - August 30 at 11:28 AM logo-$0.19 Earnings Per Share Expected for MediWound Ltd. (MDWD) This Quarter - August 28 at 6:16 AM logoMediWound Ltd. (MDWD) PT Set at $10.00 by Jefferies Group LLC - August 26 at 11:02 AM logo$740,000.00 in Sales Expected for MediWound Ltd. (NASDAQ:MDWD) This Quarter - August 11 at 9:28 AM logoMediWound Ltd. to Post FY2017 Earnings of ($0.80) Per Share, SunTrust Banks Forecasts (NASDAQ:MDWD) - August 10 at 10:42 AM logoHead to Head Contrast: Alimera Sciences (ALIM) & MediWound (NASDAQ:MDWD) - August 10 at 12:32 AM logo-$0.20 EPS Expected for MediWound Ltd. (NASDAQ:MDWD) This Quarter - August 9 at 8:24 PM logoJefferies Group Weighs in on MediWound Ltd.'s Q3 2017 Earnings (NASDAQ:MDWD) - August 7 at 7:40 AM logoEdited Transcript of MDWD earnings conference call or presentation 3-Aug-17 12:30pm GMT - August 5 at 2:39 AM logoMediWound Reports Second Quarter 2017 Financial Results - August 4 at 1:35 AM logoMediWound Ltd. (MDWD) Posts Earnings Results, Misses Estimates By $0.01 EPS - August 3 at 4:50 PM logoMediWound Ltd. (MDWD) Receives Consensus Rating of "Buy" from Analysts - July 21 at 11:19 AM logoMediWound Ltd. (NASDAQ:MDWD) Expected to Announce Earnings of -$0.19 Per Share - July 20 at 5:21 PM logoBARDA Upsizes Contract with MediWound and Exercises Option to Fund Further NexoBrid® Indications - July 20 at 12:59 AM logoMediWound Ltd. (MDWD) Expected to Announce Quarterly Sales of $670,000.00 - June 28 at 11:42 AM logo Analysts Expect MediWound Ltd. (MDWD) to Post -$0.19 EPS - June 26 at 12:30 PM logoMediWound Ltd. (MDWD) Given Consensus Recommendation of "Buy" by Brokerages - June 26 at 10:39 AM logoMediWound's (MDWD) Buy Rating Reiterated at SunTrust Banks, Inc. - June 26 at 9:04 AM logoBARDA Gives Notice of Intent to Exercise First Contract Option to Further Fund MediWound’s NexoBrid® Development - June 23 at 6:57 PM logoIndependent Study in Germany Shows NexoBrid® Reduces Average Burn Treatment Costs by nearly 30% Versus Standard of Care - June 16 at 7:26 PM logoMediWound to Present at the Jefferies Global Healthcare Conference - June 5 at 9:26 AM logoPoster Presentation Highlighting NexoBrid® Awarded “Best Poster” at the 52nd Congress of the Spanish Society of Aesthetic, Plastic and Reconstructive Surgery - June 2 at 7:54 PM logoMediwound Ltd (MDWD) Expected to Announce Quarterly Sales of $670,000.00 - June 2 at 2:54 PM logoMediwound Ltd (MDWD) Given "Buy" Rating at Aegis - May 27 at 7:00 PM logoMediWound Announces Changes to its Board of Directors - May 18 at 8:36 AM logoMediwound Ltd Expected to Post Q3 2017 Earnings of ($0.19) Per Share (MDWD) - May 11 at 9:54 AM logoQ2 2017 EPS Estimates for Mediwound Ltd (MDWD) Boosted by Jefferies Group - May 11 at 8:14 AM logoMediwound Ltd to Post Q2 2017 Earnings of ($0.21) Per Share, Oppenheimer Holdings Forecasts (MDWD) - May 11 at 8:12 AM logoMediWound Ltd. :MDWD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 - May 10 at 12:35 PM logoMediwound Ltd (MDWD) PT Set at $10.00 by Oppenheimer Holdings Inc. - May 9 at 2:34 PM logoEdited Transcript of MDWD earnings conference call or presentation 8-May-17 12:30pm GMT - May 9 at 11:52 AM logoMediwound Ltd (MDWD) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS - May 8 at 8:38 PM logoMediWound Reports First Quarter 2017 Financial Results - May 8 at 12:32 PM



MediWound (MDWD) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by Staff